Alcon offers durable global eye-care demand, improving cash generation and a discounted historical valuation, but U.S. implant competition and weak reported capital efficiency could limit earnings growth.
Medical Devices
24 tickers rated Buy in this themeGlobus Medical offers an attractive valuation backed by strong cash flow and a differentiated spine surgery ecosystem, but sustained upside depends on stabilizing Nevro demand and restoring underlying revenue growth.
Zoetis offers a potentially attractive recovery opportunity through its leading animal-health franchise, strong cash generation, and compressed valuation, although U.S. veterinary demand weakness and dermatology competition threaten future earnings growth.
Mettler-Toledo combines exceptional capital efficiency, durable precision-instrument franchises, and consistent cash generation, but its premium valuation requires sustained earnings growth and offers limited downside protection.
Insulet combines recurring Omnipod revenue, strong international growth, and improving profitability with a sharply compressed valuation, although intensifying insulin pump competition and weaker cash conversion threaten future returns.
Smith & Nephew offers an attractive medical-device recovery opportunity supported by strong sports medicine franchises and improving cash generation, although persistent US orthopedic weakness and reimbursement pressure threaten execution.
Envista offers a dental-products turnaround supported by improving margins, resilient cash generation, and reasonable valuation, although elective-procedure cyclicality and intense competition could limit the recovery.
STERIS combines recurring infection-prevention revenue, specialized sterilization infrastructure, and durable healthcare demand, but its premium cash-flow valuation and debt-financed Xodus acquisition constrain near-term upside.
Zimmer Biomet offers durable orthopedic demand, strong cash generation, and recovery potential at modest forward earnings multiples, but knee weakness, acquisition leverage, and uncertain robotics returns constrain upside.
Henry Schein offers a healthcare distribution earnings-recovery opportunity supported by share gains, margin expansion, and buybacks, although elevated leverage and modest returns on invested capital constrain its upside.
Fresenius Medical Care offers durable dialysis demand, strong free cash flow, and buyback-supported earnings recovery at a modest valuation, although reimbursement pressure, weak treatment volumes, and restructuring execution remain significant risks.
IDEXX combines a deeply integrated veterinary diagnostics ecosystem with exceptional cash generation and recurring revenue growth, but its substantial valuation premium leaves investors exposed to slower testing demand or earnings growth.